We previously identified 18q21-q22 as a candidate region for bipolar (BP) disorder and constructed a yeast artificial chromosome (YAC) contig map. Here we identified three potential CpG islands using CCG/CGG YAC fragmentation. Analysis of available genomic sequences using bioinformatic tools identified an exon of 3639 bp downstream of a CpG island of 1.2 kb containing a putative transcription initiation site. The exon contained an open reading frame coding for 1212 amino acids with significant homology to the SART-2 protein; weaker homology was found with a series of sulphotransferases. Alignment of cDNA sequences of corresponding ESTs and RT-PCR sequencing predicted a transcript of 9.5 kb which was confirmed by Northern blot analysis. The transcript was expressed in different brain areas as well as in multiple other peripheral tissues. We performed an extensive mutation analysis in 113 BP patients. A total of nine single nucleotide polymorphisms (SNPs) were identified. Five SNPs predicted an amino acid change, of which two were present in BP patients but not in 163 control individuals.
Introduction
Bipolar (BP) disorder is a severe psychiatric condition affecting about 1% of the population. The clinical signs of BP disorder are alternating episodes of depression and mania (BP type I) or hypomania (BP type II). Genetic studies have identified several potential chromosomal loci, of which chromosome 18 is of particular interest. Berrettini et al 1 first reported linkage to this chromosome in a pericentromeric region on 18p. Subsequently, several studies of chromosome 18 have been published that support a pericentromeric locus, [2] [3] [4] an 18q21-q22 locus, 2-6 both loci 7, 8 or other chromosome 18 loci. [9] [10] [11] Negative linkage studies with chromosome 18 have also been reported. 12 In further studies we refined the linkage region at 18q21-q22, identified by De Bruyn et al in a multiplex Belgian BP family, 6 to an 8.9 cM region between D18S68 and D18S979 at 18q21-q22 and constructed a physical map using yeast artificial chromosomes (YACs). 13 Our candidate region at chromosome 18q21-q22 identified in the Belgian study overlaps with that reported by Stine et al. 2 Several studies have described anticipation in families transmitting BP disorder, [14] [15] [16] suggesting the involvement of trinucleotide repeat expansions (TREs). Support for the involvement of CAG/CTG repeat expansions in BP disorder was obtained by the use of the repeat expansion detection (RED) method. 17 Genetic association of BP disorder with expanded CAG/CTG repeats was subsequently confirmed in several independent studies. [18] [19] [20] [21] However, more recently, it was shown that nearly 90% of the expanded CAG/CTG repeats detected by RED may be explained by long alleles at the polymorphic CTG18.1 and ERDA1 CAG/CTG loci present also in the normal population. [22] [23] [24] [25] [26] Also, we have excluded the involvement of CAG/CTG repeats from within the 18q21-q22 candidate region for BP disorder, 27 using a CAG repeat YAC fragmentation method. 28 Together these data make it unlikely that CAG/CTG repeats would explain the anticipation in BP families and the association in BP cases/control populations. 26 Considering that a number of diseases caused by an expansion of a CCG/CGG repeat show anticipation (reviewed by Margolis et al 16 ), we originally aimed at identifying CCG/CGG repeats from within the 18q21-q22 region using a variant of the CAG repeat YAC fragmentation method. Instead, the method was more efficient in identifying CpG islands than CCG/CGG repeats. CpG islands are considered as anchor points for genes since they are frequently observed upstream of genes in their regulatory region and are expected to play a major role in transcription control of gene expression. Using this method, we identified three CpG islands and showed that at least one is associated with a novel brain-expressed gene, which was designated C18orf4 by the HUGO Gene Nomenclature Committee. Since it is located in the candidate region 18q21-q22 for BP disorder identified in several independent studies, 2, 5, 6 we examined this gene in depth. We identified several single-nucleotide polymorphisms(SNPs) of which only two were observed in BP cases. Therefore, C18orf4 is an interesting positional candidate gene that deserves additional studies to determine its potential role in the pathogenesis of chromosome 18q21-q22-linked BP disorder.
Materials and methods

Subjects
The pedigree and the clinical diagnoses in family MAD31 were described in detail elsewhere. 13 Casecontrol studies were performed on a Belgian sample of 113 BP patients and 160 controls matched for age, sex and ethnicity. 29 All individuals were interviewed using the SADS-LA after written informed consent.
Triplet repeat isolation CCG/CGG YAC fragmentation vectors were constructed by blunt-end cloning of (CCG) 10 /(CGG) 10 adapters into the SphI site of the previously described pDV1 vector. 30 Sequencing determined that fragmentation vectors pDVCCG and pDVCGG have the adapter sequence in a 5 0 -(CCG) 10 For the RT-PCR reactions, mRNA from SHSY-5Y cells was prepared using the mMACS mRNA Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). After DNAseI treatment (Promega, Madison, WI, USA), the RT reaction was primed with oligo (dT) primers and performed with the Superscript Preamplification System for First Strand cDNA synthesis (GibcoBRL, NV Life Technologies, Merelbeke, Belgium). First-strand cDNA was used in long-range PCR reactions with TaKaRa LA Taq (Takara Shuzo Co., Otsu, Shiga, Japan). PCR products were reamplified with nested primers and sequenced as described above. 
Expression analysis
Mutation analysis
Overlapping PCR products of approximately 600 bp were generated from genomic DNA and cycle sequenced in 113 BP cases on a PE 3700 sequencer. Sequence variations were identified using the computer software program Polyphred 32 followed by visual inspection. Potential SNPs were confirmed in the BP cases by pyrosequencing using an SNP specific primer 33 on a PSQ96 apparatus (Pyrosequencing AP, Uppsala, Sweden) ( Table 1) , and analysed in 160 controls. 13, 27 Size determination by pulsed field gel electrophoresis (PFGE) and Southern blot hybridisation resulted in 33 sets of equally sized fragmented YAC clones. Sequencing of 112 fragmented YAC ends identified seven (out of 33) sets of fragmented YACs with identical end sequences resulting from a specific homologous recombination. One set (CCG7) was the result of fragmentation in a (CGG) 6 repeat. This (CGG) 6 repeat is part of a combined (CGG) 6 (CAG) 6 repeat located in the 5 0 UTR of CAP2 (GenBank accession number L40377). We had already shown that this repeat is polymorphic but not expanded in BP cases or associated with BP disorder. 27 A second set (CCG6) contained a (CCG) 2 repeat. The other five end sequence did not contain CCG/CGG repeats.
In-depth analysis showed that three (CCG3, GenBank accession number AF480432; CCG4, GenBank accession number AF480433; and CCG6, GenBank accession number AF480434) of the seven end sequences had a high CG (70-80%) and CpG (15) (16) (17) (18) (19) (20) CpGs in 200 bp) content. Primer pairs flanking these potential CpG island were used to determine their position on the YAC contig ( Figure 1 ). BLASTN analysis 34 resulted for CCG4 and CCG6 but not CCG3, in hits with sequences of RPCI-11 BACs. CCG4 gave a hit in a contig of 27 150 bp of the working draft sequence of RPCI-11 BAC 29O13 (GenBank accession number AC022662). CCG6 is part of the complete sequence of RPCI-11 BAC 793J2 (GenBank accession number AC009802).
In silico identification of C18orf4
To identify genes associated with the potential CpG islands CCG4 and CCG6, their surrounding sequences were analysed using bioinformatic tools. Hence the 27 150 bp sequence contig of BAC 29O13 and the complete sequence of BAC 793J2 were sent for analysis to the Rummage High-Throughput Sequence Annotation Server 35 (http://gen 100.imb-jena.de/rummage/index.html). First, LCP 36 and CPG 37 recognised CpG islands containing CCG4 and CCG6 of 1.2 and 0.4 kb, respectively, confirming their potential role as CpG islands.
In the next step, the exon prediction programs Grail 38 (Figure 2a) . A BLASTN search of dbEST sequences revealed significant homology (X97%) to 24 human ESTs (Figure 2b ). TBLASTX 42 searches with the ORF of the Genbank nonredundant (nr) database showed extensive homology at the protein level with SART-2 (Genbank accession number NP_037484), a squamous cell carcinoma antigen recognized by T-cells. 43 Weaker homology was found with a series of sulphotransferases. Analysis of the 1212-long amino acid sequence of the translated ORF by SMART (Simple Modular Architecture Research Tool, V3.1) 44 did not result in any known domains apart from a cleavable signal peptide at position p.1-20 and two transmembrane segments at positions p.771-791 and p.880-820 (Figure 2a) . Interpro reported no significant hits, although BLASTP 42 of the Prodom database showed homology between the ORF and the chon- Figure 1 Minimal YAC tiling path of the 18q21.3-q22 BP candidate region. 13 The YACs are represented by solid lines and the CCG/CGG fragmentation products by dotted lines. YAC sizes given between brackets were estimated by PFGE analysis. Solid circles indicate positive STS/STR hits. Shaded boxes highlight the CCG/CGG repeat in CAP2, the 3 CpG islands CCG6, CCG3 and CCG4 isolated by YAC fragmentation, and C18orf4. 
Structural organisation of C18orf4
Based on the BLASTN EST hits, I.M.A.G.E. Consortium [LLNL] cDNA clones 31 were requested and sequenced. The cDNA sequences aligned with the genomic sequence in the presumed 5 0 UTR, the ORF and the presumed 3 0 UTR, indicating that these sequences are transcribed (Figure 2c) . Alignment of the 5 0 UTR IMAGp998B194346Q2 cDNA sequence with the genomic sequence showed that an 865 bp fragment was missing in the cDNA. A detailed analysis of the flanking genomic sequences revealed the presence of consensus acceptor and donor splice sites, indicating that this fragment was most likely an intron. Clone IMAGp998D193628Q2 in the 3 0 UTR also missed a fragment of 1.9 kb when compared to the genomic sequence, but consensus splice sites flanking this sequence were absent. The cDNA clones IMAGp998L153967Q2 and IMAGp998A136826Q2 contained sequences from within the missing fragment ( Figure 2c ) while EST AA442543 was located entirely within the gap ( Figure  2b ). Two clones, IMAGp998D193628Q2 and IMAGp998A136826Q2, terminated exactly at the predicted polyadenylation signal at g.8003. Sequences of clones IMAGp998A154307Q2, IMAGp998D126826Q2 and IMAGp998F131866Q2 did not align with the genomic sequence and were not analysed further. Since cDNA clone sequencing did not result in a continuous transcript, primers were designed for RT-PCR experiments. Sequencing of overlapping RT-PCR products obtained from cultured SHSY-5Y cells confirmed the presence of a transcript of at least 9 kb, containing the ORF linked to the presumed 5 0 and 3 0 sequences (Figure 2d) . Also, the 5 0 UTR intron of 865 bp was confirmed while the 3 0 UTR was extended until the predicted polyadenylation signal at g.8003.
The novel gene was designated C18orf4 and the consensus cDNA sequence (Genbank accession number AF480435) was defined based on the genomic sequence since no sequence differences were observed between the available genomic sequence and those obtained by cDNA and RT-PCR sequencing. 
Expression pattern of C18orf4
We investigated the expression profile of C18orf4 by hybridising Northern blots of multiple tissues ( Figure  3 ). This showed the presence of an B9.5 kb transcript in lung, placenta, small intestine, liver, kidney, skeletal muscle, heart, brain, uterus, trachea, thyroid, stomach, spinal cord, prostate, mammary gland, lymph node, bladder and adrenal gland. The other investigated tissues had very weak or no expression of the transcript (thymus, colon, peripheral blood leukocyte, spleen and bone marrow). After normalisation to b-actin, the brain showed the highest relative expression (data not shown). More detailed information on the regional expression in brain was obtained by Northern blot hybridisation showing expression in all investigated areas (amygdala, caudate nucleus, corpus callosum, hippocampus, substantia nigra, thalamus and total brain).
Stringent ZOO blot hybridisation experiments identified homologous sequences in the genomic DNA of dog, pig, mouse, donkey, horse and sheep ( Figure 4 ).
Mutation analysis of C18orf4
A mutation analysis in 113 BP patients including a BPI case of the 18q21-q22-linked BP family MAD31, 13 of the complete ORF and flanking UTRs of C18orf4 was performed by sequencing overlapping fragments generated by PCR amplification of genomic DNA. Nine SNPs were identified. Three SNPs (g.À298G4A, g.À80G4A, g.1476C4G) occurred only once in the heterozygous state in the BP patients and were not analysed further. Five SNPs predicted an amino acid change (Table 1, Figure 2f ). Together with one 5 0 UTR SNP (g.À546A4G), these five coding SNPs (cSNPs) were analysed by pyrosequencing in 160 control individuals matched for ethnicity, sex and age (Table  1 ). All SNPs were in Hardy-Weinberg equilibrium. The 5 0 UTR and three of the cSNPs were present in control individuals and BP cases at near-equal allele frequencies. Also no differences in haplotype distributions were observed between BP patients and controls. The two cSNPs Y730C and I1113M appeared only in BP patients. The Y730C cSNP was hetero- Chromosome 18 positional candidate and bipolar disorder D Goossens et al zygous in one BPI patient with a positive family history. The I1113M cSNP was observed twice in the heterozygous state in a sporadic BPI patient and a familial BPII patient. The BPI patient of family MAD31 was homozygous for all SNPs except for P942S. Segregation analysis indicated that the minor allele of P942S was comprised in the risk haplotype segregating in the family (data not shown).
Discussion
We originally aimed at identifying CCG/CGG repeats from within the 18q21-q22 candidate region for BP disorder using YAC fragmentation. 28 However, instead, we isolated three sequences (CCG3, CCG4 and CCG6) that had several characteristics of CpG islands. The CCG4 sequence contained in a 1.2-kb CpG island was associated with a predicted exon of 3639 bp containing an ORF coding for a 1212 amino acid protein. This novel CpG-associated gene was designated C18orf4, of which the putative protein contains a predicted cleavable signal peptide and two potential transmembrane domains. This suggests that both the N-and C-termini are on the same side of the membrane in which the protein is embedded. C18orf4 shows a significant homology with the SART-2 protein, a squamous cell carcinoma antigen recognised by T-cells. Weaker homology was observed with a series of sulphotransferases. A sulphotransferase SULT1A1 that inactivates dopamine and other phenol-containing compounds by sulphation was also identified in a microarray expression study in rats treated with methamphetamines. 45 At the genomic level the gene sequence contained a predicted transcription start site at À2.4 kb within the CpG island, an intron of 865 bp in the 5 0 UTR and a polyadenylation signal at g.8003. The ORF was entirely contained within exon 2 of 3639 bp. C18orf4 is highly conserved among different species and is expressed as a 9.5-kb transcript in multiple tissues including all brain regions. Therefore, C18orf4 can be considered a positional and functional candidate gene for BP disorder linked to 18q21-q22. 2, 5, 6 By direct sequencing we identified nine SNPs in C18orf4 in BP patients. Five SNPs predicted an amino acid change. Two cSNPs (Y730C and I1113M) were present in the heterozygous state only in BP patients. They were, however, not observed in patients of the 18q21-q22-linked BP family MAD31. In this family, only the P942S SNP was observed that segregated with the risk haplotype. Since this SNP was also observed in controls (minor allele frequency 0.01), it is unlikely that this variant C18orf4 explains the disease aggregation in this family.
In conclusion, our study did not support a role for expanded CCG/CGG repeats from within the 18q21-q22 region in BP disorder. However, we identified within the 18q21-q22 candidate region one novel CpG-associated gene C18orf4 that is widely expressed, including in the brain. Owing to its localisation on chromosome 18, in a region that we and others previously linked to BP disorder, 13, 10 as well as the identification of two cSNPs present only in BP cases, we cannot exclude a potential role for C18orf4 in BP disorder. The predicted sequence similarities, although suggestive, do not provide substantial clues on its potential function in BP pathogenesis.
Therefore, studies of the C18orf4 SNPs will be needed in independent BP case/control samples and chromosome 18q21-q22 families to confirm that C18orf4 is a candidate gene for chromosome 18q21-q22-linked BP disorder. 
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